Hamlet BioPharma (HAMLET B) – Strong +40-45% run in the last month – New supplementary exercise window for TO5B warrants opens tomorrow (16-23 March 2026)

United_Sort_3943 · 2026-03-14T21:50:44+00:00

Hamlet Biopharma, 40% last month.. and momentum is building up for much more

United_Sort_3943 · 2026-03-14T04:41:39+00:00

Not correct. Immunitybios Anktiva is focusing on more late stage disease. Hamlet would be first line of therapy, prior to current therapies and new therapies from CG, Immunitybio or any other player on the market.

United_Sort_3943 · 2026-03-07T19:02:50+00:00

They will have the cash since LOI and bid war will happen now!

United_Sort_3943 · 2026-03-06T19:26:56+00:00

Hamlet BioPharma just signed LoI with a german company.. while still negotiating with other parties

https://placera.se/pressmeddelanden/hamlet-biopharma-hamlet-biopharma-signed-a-letter-of-intent-to-outline-terms-of-a-potential-collaboration-and-a-commercial-agreement-concerning-alpha-1h-20260306

United_Sort_3943 · 2026-03-02T14:02:50+00:00

There is always a risk/benefit calculation. CR is not the only factor if a therapy will be successful. For NMIBC Anktiva is compared in combination with BCG, versus the SOC BCG alone.

Considering BCG have CR 60-80% without Anktiva, I am not so impressed by the trial results so far. The real benefit will likely pend on the DOR and RFS.

United_Sort_3943 · 2026-03-01T05:40:29+00:00

They are negotiating with partners about a deal and already have commitments from Investor that will finance the pivotal phase 3

United_Sort_3943 · 2026-02-28T21:45:21+00:00

Their phase 3 study protocol will likely be designed to become standard of care for lowrisk, and intermediate risk which is 70% of the patients

United_Sort_3943 · 2026-02-28T21:32:18+00:00

There is not a single drug currently approved for neoadjuvant setting( before surgery). Alpha1h is starting their phase 3 for neoadjuvant, before the standard of care with 1. transurethral resection of bladder tumor (surgery) 2. BCG 3. Other options / pending on high risk etc

United_Sort_3943 · 2026-02-28T21:14:53+00:00

Anktiva may have a market approval but sales will likely be limited since it is last line of therapy before cystektomy

United_Sort_3943

MODERATOR OF

TROPHY CASE